Aptose Biosciences (APTO) 10-K2021 FY Annual report

Filed: 22 Mar 22, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AEs, AHSC, analog, AURK, baseline, Biden, Bio, bridging, chemotherapy, Congressional, constellation, constitutionality, counting, CR, CRc, CRi, Crystal, decitabine, defensive, dismissed, double, durable, emavusertib, embedded, entospletinib, ESPP, forfeited, Hanmi, hematopoietic, HSCT, ID, Instance, inventory, irrevocable, JAK, judicial, kinome, Kura, lanraprenib, licensee, Linkbase, lt, LYN, match, menin, mild, MKI, modification, modulation, monotherapy, nemtabrutinib, objective, overcome, payroll, PDGRF, peak, percent, perpetual, phosphorylation, pill, pirtobrutinib, PR, PSO, reacquired, reconsider, reexamining, regression, resource, Schema, settlement, sponsorship, stem, Supreme, Syndax, Taxonomy, transplant, unclear, understated, unfit, unnecessary, unvested, Vaughan, whichever, WM, WT

Removed: aberrant, abnormal, acceptor, Accountant, activation, activator, added, agreed, ahead, appendiceal, ASU, asymptomatic, Aurora, Australian, azacytidine, BA, Banking, Barbara, BDO, bearing, bind, biomarker, branch, broadening, Cantor, Century, characterization, Chinese, CN, cohort, collected, colorectal, committed, compromised, confirmed, contrast, craft, cumulative, deductibility, defer, deficiency, denied, depleting, derivative, discovering, DNA, Dysregulation, effort, element, elucidate, elucidating, encouraging, enzymatic, epigenetically, eradication, escalated, essential, evaluable, expanded, exploit, exploratory, explore, Extensible, family, Fargo, fatigue, Figure, Fitzgerald, flexibility, formatted, France, fundamentally, gene, green, Houston, Howell, inactive, infusion, intention, investigator, irreversibly, Italy, iv, Jennifer, Language, leukemic, lifted, Likewise, limitation, liver, lowering, lung, maturation, median, Memorial, Michael, mishap, mononuclear, mRNA, nationalized, necropsy, notified, NSCLC, occurring, oncologic, oncoprotein, overexpressed, overlap, owner, passed, path, PBMC, PCT, Pennsylvania, phosphate, placement, preclinically, predictive, prognostic, prolonged, promoter, prone, purified, reactivity, RECIST, recommended, recurring, red, region, relaxing, repeal, repealing, repertoire, replace, replacement, restarted, restating, restoring, restraining, resubmission, reveal, Roche, root, Santa, science, Seidman, shrinkage, SLS, sodium, soluble, solve, Spain, speculated, splenomegaly, stabilize, stable, Stephen, stop, suggestive, suit, sulfate, supplementation, suppressant, TCJA, temporarily, territorial, Transcutol, transformation, transporter, Trump, typical, unanticipated, uncontrolled, unresponsive, upstream, usage, uterine, utilize, validated, vehicle, visible, voluntary, waive, Wedbush, week, weekly, Wharton, Wheler

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated APTO transcripts

APTO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, William G. Rice, the President and Chief Executive Officer of Aptose Biosciences Inc. (the “Company”), hereby certify that, to my knowledge:

1. The Annual Report on Form 10-K for the year ended December 31, 2021 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 22, 2022

/s/ William G. Rice

Name: William G. Rice, Ph.D.

Title: President and Chief Executive Officer